JAGX
Jaguar HealthANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
9
U.S. public peers
Grade Position
Above peers
vs peer average
JAGX vs peer average
86/100
JAGX vs. peer average (A vs. C)
Grade spread
A 1 · B 1 · C 3 · D 3 · F 1
Graded peers loaded
Coverage
9 graded
100% of tracked
Peer overview
TAK is the first available peer comparator.
Takeda's approved GATTEX provides an SBS treatment reference, not an MVID or micro-cap valuation comparable. [Company release](https://www.takeda.com/en-us/newsroom/news-releases/2019/us-fda-approves-gattex-teduglutide-for-children-1-year-of-age-and-older-with-short-bowel-syndrome-sbs/).
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
JAGX
Jaguar Health
TAK
Takeda Pharmaceutical
Grade
A
B
Momentum
1
91
Value
41
63
Sentiment
100
45
Setup Bias
Net —
-
Market Cap
-
-
Posture
Constructive
Constructive
Grade position vs TAK
JAGX / TAK
Grade Position
Above peers
JAGX vs. peer average (A vs. C)
86/100
Momentum
1
TAKValue
41
TAKSentiment
100
JAGXRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs JAGX
TAK is the first peer returned for this comparison set.